Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Small Cell Lung Cancer · Small Cell Lung Cancer ( SCLC ) · Transformed Small Cell Lung Cancer · Lung Neoplasms · Carcinoma, Small Cell Lung · Small Cell Cancer Of The Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Jul 2, 2026
- Main results expected
- Mar 24, 2028
- Fully finished
- Mar 24, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Measured over: From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
Number of Participants with Adverse Events (AEs)
Measured over: Up to 90 days after the last dose of treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07476287 · record last updated 2026-10-09 · checked 2026-11-09 15:36 UTC